Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

MAOA-VNTR Genotype Effects on Ventral Striatum-Hippocampus Network in Alzheimer's Disease: Analysis Using Structural Covariance Network and Correlation with Neurobehavior Performance.

Chang HI, Chang YT, Tsai SJ, Huang CW, Hsu SW, Liu ME, Chang WN, Lien CY, Huang SH, Lee CC, Chang CC.

Mol Neurobiol. 2018 Oct 18. doi: 10.1007/s12035-018-1394-0. [Epub ahead of print]

PMID:
30338484
2.

Exome Pool-Seq in neurodevelopmental disorders.

Popp B, Ekici AB, Thiel CT, Hoyer J, Wiesener A, Kraus C, Reis A, Zweier C.

Eur J Hum Genet. 2017 Dec;25(12):1364-1376. doi: 10.1038/s41431-017-0022-1. Epub 2017 Nov 20.

3.

Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease.

Tajeddinn W, Persson T, Calvo-Garrido J, Seed Ahmed M, Maioli S, Vijayaraghavan S, Kazokoglu MS, Parrado-Fernández C, Yoshitake T, Kehr J, Francis P, Winblad B, Höglund K, Cedazo-Minguez A, Aarsland D.

J Alzheimers Dis. 2016 May 7;53(1):349-61. doi: 10.3233/JAD-160046.

PMID:
27163814
4.

5-HT1B and other related serotonergic proteins are altered in APPswe mutation.

Tajeddinn W, Persson T, Maioli S, Calvo-Garrido J, Parrado-Fernandez C, Yoshitake T, Kehr J, Francis P, Winblad B, Höglund K, Cedazo-Minguez A, Aarsland D.

Neurosci Lett. 2015 May 6;594:137-43. doi: 10.1016/j.neulet.2015.03.064. Epub 2015 Apr 1.

PMID:
25841787
5.

Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: a 90-month longitudinal study.

Scholz CJ, Jungwirth S, Danielczyk W, Weber H, Wichart I, Tragl KH, Fischer P, Riederer P, Deckert J, Grünblatt E.

Am J Med Genet B Neuropsychiatr Genet. 2014 Mar;165B(2):184-91. doi: 10.1002/ajmg.b.32220. Epub 2014 Jan 17.

PMID:
24443391
6.

Genetic risk factors for depression in Alzheimer`s disease patients.

Arlt S, Demiralay C, Tharun B, Geisel O, Storm N, Eichenlaub M, Lehmbeck JT, Wiedemann K, Leuenberger B, Jahn H.

Curr Alzheimer Res. 2013 Jan;10(1):72-81.

PMID:
23157339
7.

Connectomic intermediate phenotypes for psychiatric disorders.

Fornito A, Bullmore ET.

Front Psychiatry. 2012 Apr 19;3:32. doi: 10.3389/fpsyt.2012.00032. eCollection 2012.

8.

Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells.

Liu YJ, Meng FT, Wang LL, Zhang LF, Cheng XP, Zhou JN.

J Pineal Res. 2012 May;52(4):397-402. doi: 10.1111/j.1600-079X.2011.00954.x. Epub 2012 Jan 8.

PMID:
22225631
9.
10.

In vitro assays fail to predict in vivo effects of regulatory polymorphisms.

Cirulli ET, Goldstein DB.

Hum Mol Genet. 2007 Aug 15;16(16):1931-9. Epub 2007 Jun 12.

PMID:
17566082
11.

Monoamine oxidase a polymorphism in Brazilian patients: risk factor for late-onset Alzheimer's disease?

Nishimura AL, Guindalini C, Oliveira JR, Nitrini R, Bahia VS, de Brito-Marques PR, Otto PA, Zatz M.

J Mol Neurosci. 2005;27(2):213-7.

PMID:
16186632
12.

TCH-346 (Novartis).

Mück-Seler D, Pivac N.

IDrugs. 2000 May;3(5):530-5.

PMID:
16100686
13.

Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity.

Tao G, Irie Y, Li DJ, Keung WM.

Bioorg Med Chem. 2005 Aug 1;13(15):4777-88.

PMID:
15936201
14.

Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant.

Takehashi M, Tanaka S, Masliah E, Ueda K.

Neurosci Lett. 2002 Jul 19;327(2):79-82.

PMID:
12098640
15.

Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients.

Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N, Jazin EE.

Neurosci Lett. 2002 Jun 21;326(1):56-60.

PMID:
12052537

Supplemental Content

Loading ...
Support Center